Clinical impacts of positive intraepithelial neoplasia at pancreatic transection margin in pancreatic cancer surgery.

Carcinoma Intraepithelial neoplasia Pancreatic ductal Recurrence Transection margin

Journal

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
ISSN: 1424-3911
Titre abrégé: Pancreatology
Pays: Switzerland
ID NLM: 100966936

Informations de publication

Date de publication:
15 Feb 2024
Historique:
received: 05 09 2023
revised: 02 02 2024
accepted: 09 02 2024
medline: 21 2 2024
pubmed: 21 2 2024
entrez: 20 2 2024
Statut: aheadofprint

Résumé

The outcomes of patients with intraepithelial neoplasia at the pancreatic transection margin after pancreatic cancer surgery remain unclear. We evaluated the clinical impact of pancreatic transection margin status. This retrospective observational study included 171 patients who underwent surgery for pancreatic ductal adenocarcinoma between January 2008 and December 2019. Patients were classified into three groups: negative pancreatic transection margin (group N), positive low-grade (group L), and positive high-grade (group H) intraepithelial neoplasia. The clinicopathological findings and prognoses were analyzed for each group. There were 140, 14, and 9 patients in groups N, L, and H, respectively. The median age was significantly higher in group H (p = 0.035). There were no significant differences in male ratio, preoperative chemotherapy administration rate, pretreatment tumor markers, operative procedure, operative time, or blood loss. Overall survival and recurrence-free survival were not significantly different; however, the cumulative risk of recurrence in the remnant pancreas was significantly higher in group H (p = 0.018). Intraepithelial neoplasia at the pancreatic transection margin did not affect overall/recurrence-free survival. As patients with high-grade intraepithelial neoplasia at the pancreatic transection margin have an increased risk of recurrence in the remnant pancreas, careful postoperative follow-up is required.

Sections du résumé

BACKGROUND/OBJECTIVES OBJECTIVE
The outcomes of patients with intraepithelial neoplasia at the pancreatic transection margin after pancreatic cancer surgery remain unclear. We evaluated the clinical impact of pancreatic transection margin status.
METHODS METHODS
This retrospective observational study included 171 patients who underwent surgery for pancreatic ductal adenocarcinoma between January 2008 and December 2019. Patients were classified into three groups: negative pancreatic transection margin (group N), positive low-grade (group L), and positive high-grade (group H) intraepithelial neoplasia. The clinicopathological findings and prognoses were analyzed for each group.
RESULTS RESULTS
There were 140, 14, and 9 patients in groups N, L, and H, respectively. The median age was significantly higher in group H (p = 0.035). There were no significant differences in male ratio, preoperative chemotherapy administration rate, pretreatment tumor markers, operative procedure, operative time, or blood loss. Overall survival and recurrence-free survival were not significantly different; however, the cumulative risk of recurrence in the remnant pancreas was significantly higher in group H (p = 0.018).
CONCLUSIONS CONCLUSIONS
Intraepithelial neoplasia at the pancreatic transection margin did not affect overall/recurrence-free survival. As patients with high-grade intraepithelial neoplasia at the pancreatic transection margin have an increased risk of recurrence in the remnant pancreas, careful postoperative follow-up is required.

Identifiants

pubmed: 38378436
pii: S1424-3903(24)00032-2
doi: 10.1016/j.pan.2024.02.005
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors have no conflicts of interest to disclose.

Auteurs

Satoshi Takada (S)

Department of Hepato-Biliary-Pancreatic Surgery and Transplantation, Kanazawa University, Japan. Electronic address: s.takada@med.kanazawa-u.ac.jp.

Isamu Makino (I)

Department of Hepato-Biliary-Pancreatic Surgery and Transplantation, Kanazawa University, Japan.

Kaoru Katano (K)

Department of Hepato-Biliary-Pancreatic Surgery and Transplantation, Kanazawa University, Japan.

Hiroaki Sugita (H)

Department of Hepato-Biliary-Pancreatic Surgery and Transplantation, Kanazawa University, Japan.

Tomokazu Tokoro (T)

Department of Hepato-Biliary-Pancreatic Surgery and Transplantation, Kanazawa University, Japan.

Ryosuke Gabata (R)

Department of Hepato-Biliary-Pancreatic Surgery and Transplantation, Kanazawa University, Japan.

Mitsuyoshi Okazaki (M)

Department of Hepato-Biliary-Pancreatic Surgery and Transplantation, Kanazawa University, Japan.

Shinichi Nakanuma (S)

Department of Hepato-Biliary-Pancreatic Surgery and Transplantation, Kanazawa University, Japan.

Hiroko Ikeda (H)

Department of Diagnostic Pathology, Kanazawa University Hospital, Japan.

Tadashi Toyama (T)

Innovative Clinical Research Center, Kanazawa University, Japan.

Shintaro Yagi (S)

Department of Hepato-Biliary-Pancreatic Surgery and Transplantation, Kanazawa University, Japan.

Classifications MeSH